Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
GNRHR encodes the receptor for type 1 gonadotropin-releasing hormone. Additionally we are shipping GNRHR Kits (32) and GNRHR Proteins (4) and many more products for this protein.
Showing 10 out of 126 products:
Human Monoclonal GNRHR Primary Antibody for IHC (fro), FACS - ABIN966217
Karande, Rajeshwari, Schol, Hilgers: Establishment of immunological probes to study human gonadotropin-releasing hormone receptors. in Molecular and cellular endocrinology 1996
Show all 5 Pubmed References
Goat Polyclonal GNRHR Primary Antibody for IF (p), IHC (p) - ABIN686917
Liu, Li, Zhu, Yu, Guo, Zhou, Zheng, Qu, Huang, Chen, Wang, Ye: Effects of di-(2-ethylhexyl) phthalate on the hypothalamus-pituitary-ovarian axis in adult female rats. in Reproductive toxicology (Elmsford, N.Y.) 2014
Show all 2 Pubmed References
Human Polyclonal GNRHR Primary Antibody for ELISA, WB - ABIN188695
Yeung, An, Cheng, Chow, Leung: Expression and transcriptional regulation of the GnRH receptor gene in human neuronal cells. in Molecular human reproduction 2006
c.364C>T in GNRHR is a complete loss-of-function mutation which caused idiopathic hypogonadotropic hypogonadism.
GNRHR (and GNRH) are expressed in trophoblast cell populations and fallopian tube epithelium at tubal ectopic pregnancy sites.
first description of a GNRHR gene mutation in three patients diagnosed with polycystic ovary syndrome.
We showed that GNRHR and LHCGR were highly expressed in some wildtype aldosterone-producing adenoma samples, and that they positively correlated with GnRH-stimulated aldosterone production.
Results show that biallelic gonadotropin releasing hormone receptor (GNRHR) mutations are not a frequent cause of age-related androgen decline in men.
GnRH receptors on triple negative breast cancer cells can be used for targeted therapy of these cancers with GnRH agonist triptorelin
study found a novel mutation in PROK2 (show PROK2 Antibodies) in two male siblings presenting normosmic congenital hypogonadotropic hypogonadism, in whom a mutation in the GNRHR gene had been previously described, suggesting the possibility of a digenic inheritance
Data suggest differences in regulation of expression of PEDF (show SERPINF1 Antibodies) (up-regulation) vs. VEGF (show VEGFA Antibodies) (down-regulation) in granulosa cells explain reduced risk of ovarian hyperstimulation syndrome due to ovulation induction using GnRH (show GNRH1 Antibodies)/GNRHR agonists rather than hCG (show CGA Antibodies).
A high prevalence of endometriosis, polymorphism in the LHCGR and GnRH1 and progonadoliberin-2 antibodies in serum was found among the patients with severe dysmotility after treatment with GnRH analogs.
No abnormalities were found in the patient group for the PROKR2 (show PROKR2 Antibodies) and GNRH1genes. In addition, no genomic rearrangements were identified in the healthy control individuals for the described genes
These results suggest that GNRHR-I is constitutively expressed in rabbit corpora lutea independently of luteal stage of pseudopregnant rabbits.
leptin's direct stimulatory actions on gonadotrope GnRHR correlate with a direct inhibition of expression of the posttranscriptional regulator MSI1 (show MSI1 Antibodies). There also is a direct MSI1 (show MSI1 Antibodies) interaction with 3'-UTR (show UTS2R Antibodies) of Gnrhr mRNA.
the age-dependent basal and regulated Gnrhr transcription could account for the initial blockade and subsequent activation of the reproductive system during development.
GnRH (show GNRH1 Antibodies)-GnRHR system is not essential for growth or motor/sensory/orientation behavior during the first month of life prior to puberty onset. The lack of the GnRH (show GNRH1 Antibodies)-GnRHR axis, however, did affect females resulting in reduced subcutaneous inguinal fat pad (show DHX40 Antibodies) weight and increased glucose with possible insulin (show INS Antibodies) resistance.
His305 of the GnRH receptor forms two distinct interactions that determine binding to GnRH and couple agonist binding to the conserved transmembrane domain network that activates GPCRs.
The aims of this study were to explore whether mRNA-levels of gonadotropin-releasing hormone (Gnrh (show GNRH1 Antibodies)) and its receptor (Gnrhr) were changed in plaque-bearing Alzheimer's disease transgenic mice.
Data confirm that Gnrhr mRNA and protein are expressed in ovaries, granulosa cells, cumulus cells, and oocytes.
Msx1 (show MSX1 Antibodies) functions as a negative regulator early in pituitary development by repressing the gonadotrope-specific alphaGSU (show CGA Antibodies) and GnRHR genes.
These results suggest decreased GnRH receptor signaling in the mutant animal, compared with wild type.
Report down-regulation of ErbB4 (show ERBB4 Antibodies) expression in hypothalamic neurons induced by G-protein-coupled gonadotropin releasing hormone receptor stimulation.
GnRHR neurons were found in different brain areas. Many GnRHR neurons were identified in areas influencing sexual behaviors
The GRIA1 (show GRIA1 Antibodies) polymorphism exists in beef cows but it does not influence antral follicle numbers. The association between GnRHR genotype and age at first calving is likely not causal as this polymorphism is not functional.
There was a significant correlation between frequency profile and timing of puberty among the studied breeds, which seems to suggest that genetic variation within bovine GNRHR gene could explain at least part of the reported variability.
These results indicate that GnRHR gene can be a potential marker for improving sperm quality traits, and imply that bulls with GA or CT genotype should be selected in breeding program.
Seven sequence variants (SVs) have been identified in exon 1 and in the promoter region upstream of the bovine gonadotrophin releasing hormone (GnRH) receptor; g.-108T>C alteration was associated with beneficial effects on fertility
Data show that GnRH (show GNRH1 Antibodies) stimulates phagocytosis in fish leucocytes through a GnRH-receptor-dependent pathway.
This gene encodes the receptor for type 1 gonadotropin-releasing hormone. This receptor is a member of the seven-transmembrane, G-protein coupled receptor (GPCR) family. It is expressed on the surface of pituitary gonadotrope cells as well as lymphocytes, breast, ovary, and prostate. Following binding of gonadotropin-releasing hormone, the receptor associates with G-proteins that activate a phosphatidylinositol-calcium second messenger system. Activation of the receptor ultimately causes the release of gonadotropic luteinizing hormone (LH) and follicle stimulating hormone (FSH). Defects in this gene are a cause of hypogonadotropic hypogonadism (HH). Alternative splicing results in multiple transcript variants encoding different isoforms. More than 18 transcription initiation sites in the 5' region and multiple polyA signals in the 3' region have been identified for this gene.
, gonadotropin-releasing hormone (type 1) receptor 1
, leutinizing hormone releasing horomone receptor
, leutinizing-releasing hormone receptor
, luliberin receptor
, type I GnRH receptor
, GnRH receptor
, gonadotropin-releasing hormone receptor
, gonadotropin releasing hormone receptor
, growth hormone
, luteinizing-releasing hormone receptor
, gnoadotropin releasing hormone receptor 2
, gonadotropin-releasing hormone II receptor
, type 1/III gonadotropin-releasing hormone receptor hexahelical
, type 3/II gonadotropin-releasing hormone receptor
, pituitary GnRH receptor
, pituitary gonadotropin-releasing hormone receptor
, luteinizing hormone-releasing hormone receptor